• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国每预防一例 COVID-19 感染可避免的质量调整生命年损失。

Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States.

机构信息

The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.

Department of Economics, University of California, San Diego, CA, USA.

出版信息

Value Health. 2021 May;24(5):632-640. doi: 10.1016/j.jval.2020.11.013. Epub 2021 Mar 8.

DOI:10.1016/j.jval.2020.11.013
PMID:33933231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7938736/
Abstract

OBJECTIVE

To estimate the overall quality-adjusted life-years (QALYs) gained by averting 1 coronavirus disease 2019 (COVID-19) infection over the duration of the pandemic.

METHODS

A cohort-based probabilistic simulation model, informed by the latest epidemiological estimates on COVID-19 in the United States provided by the Centers for Disease Control and Prevention and literature review. Heterogeneity of parameter values across age group was accounted for. The main outcome studied was QALYs for the infected patient, patient's family members, and the contagion effect of the infected patient over the duration of the pandemic.

RESULTS

Averting a COVID-19 infection in a representative US resident will generate an additional 0.061 (0.016-0.129) QALYs (for the patient: 0.055, 95% confidence interval [CI] 0.014-0.115; for the patient's family members: 0.006, 95% CI 0.002-0.015). Accounting for the contagion effect of this infection, and assuming that an effective vaccine will be available in 3 months, the total QALYs gains from averting 1 single infection is 1.51 (95% CI 0.28-4.37) accrued to patients and their family members affected by the index infection and its sequelae. These results were robust to most parameter values and were most influenced by effective reproduction number, probability of death outside the hospital, the time-varying hazard rates of hospitalization, and death in critical care.

CONCLUSION

Our findings suggest that the health benefits of averting 1 COVID-19 infection in the United States are substantial. Efforts to curb infections must weigh the costs against these benefits.

摘要

目的

估计在大流行期间避免 1 例新冠肺炎(COVID-19)感染所获得的总体质量调整生命年(QALYs)。

方法

基于美国疾病控制与预防中心提供的最新 COVID-19 流行病学估计和文献回顾,采用基于队列的概率模拟模型。考虑了参数值在年龄组之间的异质性。研究的主要结果是感染患者、患者家属以及感染患者在大流行期间的传染效应的 QALYs。

结果

避免代表性美国居民感染 COVID-19 将产生额外的 0.061(0.016-0.129)QALYs(患者:0.055,95%置信区间[CI] 0.014-0.115;患者家属:0.006,95%CI 0.002-0.015)。考虑到这种感染的传染效应,并假设 3 个月后将有有效的疫苗,避免 1 例单一感染所带来的总 QALYs 收益为 1.51(95%CI 0.28-4.37),惠及受指数感染及其后遗症影响的患者及其家属。这些结果对大多数参数值都是稳健的,最受有效繁殖数、医院外死亡率、住院和重症监护的时变危险率的影响。

结论

我们的研究结果表明,避免美国 1 例 COVID-19 感染的健康益处是巨大的。遏制感染的努力必须权衡成本与这些益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5be5/7938736/e160918c789b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5be5/7938736/c752d08e64bd/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5be5/7938736/a82bb6b4c673/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5be5/7938736/e160918c789b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5be5/7938736/c752d08e64bd/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5be5/7938736/a82bb6b4c673/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5be5/7938736/e160918c789b/gr3_lrg.jpg

相似文献

1
Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States.美国每预防一例 COVID-19 感染可避免的质量调整生命年损失。
Value Health. 2021 May;24(5):632-640. doi: 10.1016/j.jval.2020.11.013. Epub 2021 Mar 8.
2
Quality adjusted life years in the time of COVID-19.在 COVID-19 时代的质量调整生命年。
Aust Health Rev. 2021 Feb;45(1):12-13. doi: 10.1071/AH21010.
3
4
Indirect COVID-19 health effects and potential mitigating interventions: Cost-effectiveness framework.间接 COVID-19 健康影响及其潜在缓解干预措施:成本效益框架。
PLoS One. 2022 Jul 18;17(7):e0271523. doi: 10.1371/journal.pone.0271523. eCollection 2022.
5
Impact of school closures for COVID-19 on the US health-care workforce and net mortality: a modelling study.新冠疫情期间学校关闭对美国医护人员队伍和净死亡率的影响:建模研究。
Lancet Public Health. 2020 May;5(5):e271-e278. doi: 10.1016/S2468-2667(20)30082-7. Epub 2020 Apr 3.
6
The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.HIV感染女性宫颈癌筛查的成本、临床益处及成本效益
Ann Intern Med. 1999 Jan 19;130(2):97-107. doi: 10.7326/0003-4819-130-2-199901190-00003.
7
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.帕利珠单抗用于预防早产儿呼吸道合胞病毒感染的成本效用分析:基于西班牙临床证据的更新
BMC Infect Dis. 2017 Oct 17;17(1):687. doi: 10.1186/s12879-017-2803-0.
8
Cost-utility analysis of cataract surgery in the second eye.第二只眼白内障手术的成本效用分析
Ophthalmology. 2003 Dec;110(12):2310-7. doi: 10.1016/S0161-6420(03)00796-6.
9
The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.双耳重度至极重度感音神经性聋成人中,双侧与单侧及双侧人工耳蜗植入的成本-效果比较。
Ear Hear. 2019 Nov/Dec;40(6):1425-1436. doi: 10.1097/AUD.0000000000000727.
10
Interval Appendectomy: Finding the Breaking Point for Cost-Effectiveness.间隔期阑尾切除术:探寻成本效益的临界点
J Am Coll Surg. 2016 Oct;223(4):632-43. doi: 10.1016/j.jamcollsurg.2016.07.015. Epub 2016 Aug 5.

引用本文的文献

1
Mobile Distribution of COVID-19 Vaccines to Migrant Farmworkers in Minnesota.明尼苏达州向流动农民工分发 COVID-19 疫苗。
J Agromedicine. 2024 Jan;29(1):106-111. doi: 10.1080/1059924X.2023.2278804. Epub 2023 Dec 28.
2
Cost benefit analysis of alternative testing and quarantine policies for travelers for infection control: A case study of Singapore during the COVID-19 pandemic.替代旅行者检测和检疫政策的成本效益分析,以控制感染:COVID-19 大流行期间新加坡的案例研究。
Front Public Health. 2023 Feb 23;11:1101986. doi: 10.3389/fpubh.2023.1101986. eCollection 2023.
3
Economic Analysis of Border Control Policies during COVID-19 Pandemic: A Modelling Study to Inform Cross-Border Travel Policy between Singapore and Thailand.

本文引用的文献

1
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
2
Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses.严重急性呼吸综合征冠状病毒2型疫苗接种的流行病学影响:数学建模分析
Vaccines (Basel). 2020 Nov 9;8(4):668. doi: 10.3390/vaccines8040668.
3
Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations.
《COVID-19 大流行期间边境管控政策的经济分析:为新泰边境旅行政策提供信息的建模研究》
Int J Environ Res Public Health. 2023 Feb 23;20(5):4011. doi: 10.3390/ijerph20054011.
4
Economic evaluation of COVID-19 rapid antigen screening programs in the workplace.工作场所 COVID-19 快速抗原筛查计划的经济评价。
BMC Med. 2022 Nov 23;20(1):452. doi: 10.1186/s12916-022-02641-5.
5
Valuing COVID-19 Morbidity Risk Reductions.重视新冠病毒感染所致疾病发病率的降低
J Benefit Cost Anal. 2022 Summer;13(2):247-268. doi: 10.1017/bca.2022.11. Epub 2022 Aug 3.
6
Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands.因 COVID-19 死亡率而导致的质量调整生命年损失:荷兰的方法和应用。
Value Health. 2022 May;25(5):731-735. doi: 10.1016/j.jval.2021.12.008. Epub 2022 Feb 3.
7
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues.COVID-19 干预措施的经济评价系统综述:考虑非健康影响和分配问题。
Value Health. 2022 Aug;25(8):1298-1306. doi: 10.1016/j.jval.2022.02.003. Epub 2022 Apr 6.
8
A model framework for projecting the prevalence and impact of Long-COVID in the UK.用于预测英国长期 COVID 患病率和影响的模型框架。
PLoS One. 2021 Dec 2;16(12):e0260843. doi: 10.1371/journal.pone.0260843. eCollection 2021.
9
Effect of easing lockdown and restriction measures on COVID-19 epidemic projection: A case study of Saudi Arabia.放松封锁和限制措施对 COVID-19 疫情预测的影响:以沙特阿拉伯为例的研究。
PLoS One. 2021 Sep 9;16(9):e0256958. doi: 10.1371/journal.pone.0256958. eCollection 2021.
10
Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic.应对2019年冠状病毒大流行干预措施的卫生经济学
Value Health. 2021 May;24(5):605-606. doi: 10.1016/j.jval.2021.03.002. Epub 2021 Apr 16.
抗病毒治疗在大流行和呼吸道疾病(包括 COVID-19)暴发中的成本效益:已发表经济评估的系统综述。
Value Health. 2020 Nov;23(11):1409-1422. doi: 10.1016/j.jval.2020.07.002. Epub 2020 Sep 6.
4
Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research.COVID-19 的潜伏期:一项针对观察性研究的快速系统评价和荟萃分析。
BMJ Open. 2020 Aug 16;10(8):e039652. doi: 10.1136/bmjopen-2020-039652.
5
COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection.新型冠状病毒肺炎与地塞米松:一种避免类固醇相关类圆线虫超感染的潜在策略
JAMA. 2020 Aug 18;324(7):623-624. doi: 10.1001/jama.2020.13170.
6
Estimation of time-varying reproduction numbers underlying epidemiological processes: A new statistical tool for the COVID-19 pandemic.估计流行病学过程中时变的繁殖数:COVID-19 大流行的新统计工具。
PLoS One. 2020 Jul 21;15(7):e0236464. doi: 10.1371/journal.pone.0236464. eCollection 2020.
7
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
8
Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis.COVID-19 住院患者的急性并发症和死亡率:系统评价和荟萃分析。
Crit Care. 2020 Jul 2;24(1):389. doi: 10.1186/s13054-020-03022-1.
9
COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors.COVID-19 相关心脏损伤:对幸存者长期监测和结局的影响。
Heart Rhythm. 2020 Nov;17(11):1984-1990. doi: 10.1016/j.hrthm.2020.06.026. Epub 2020 Jun 26.
10
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.